BACTERIAL BIOFILM FORMATION AND QUORUM SENSING: MOLECULAR MECHANISMS, CLINICAL SIGNIFICANCE, AND ANTI-BIOFILM THERAPEUTIC STRATEGIES

Abstract

Background: Bacterial biofilms—structured, surface-attached microbial communities encased in a self-produced extracellular polymeric substance (EPS) matrix—represent the predominant mode of bacterial existence in natural and clinical environments. Biofilm-associated infections account for over 65% of all human microbial infections and 80% of chronic infections, are 10–1,000-fold more resistant to antibiotics than planktonic counterparts, and are responsible for the majority of device-related nosocomial infections. Quorum sensing (QS)—the cell density-dependent, signal molecule-mediated gene regulation system that coordinates biofilm formation, virulence factor expression, and antibiotic resistance—is the central molecular regulatory mechanism linking bacterial population density to pathogenic behaviour.

Objective: To provide a concise, evidence-based review of the molecular stages of biofilm development, the chemical biology of quorum sensing signal molecules in Gram-positive and Gram-negative bacteria, mechanisms of biofilm antibiotic tolerance, and current and emerging anti-biofilm therapeutic strategies including quorum quenching, dispersal agents, and combination biofilm-active regimens.

Methods: A systematic review of eight primary peer-reviewed sources—landmark molecular studies, comprehensive reviews, and clinical research published between 1998 and 2024—was conducted.

Results: Biofilm formation proceeds through five stages—reversible attachment, irreversible attachment, microcolony formation, biofilm maturation, and dispersal—regulated by cyclic-di-GMP (c-di-GMP) as the master intracellular second messenger. Gram-negative LuxI/LuxR N-acyl-homoserine lactone (AHL) QS systems and Gram-positive RNAIII-mediated agr systems control biofilm maturation and virulence gene expression. Biofilm EPS matrix reduces effective antibiotic concentration 10–1,000-fold through diffusion limitation, charge neutralization, and phenotypic heterogeneity including persister cell formation. Anti-biofilm strategies—DNase I, dispersin B (DspB), QS inhibitors (furanones, halogenated amine QQ enzymes), and targeted combination regimens—reduce biofilm biomass by 60–90% in vitro and improve clinical outcomes in device-related infections.

Conclusion: Biofilm formation and quorum sensing constitute the central molecular framework for understanding chronic and device-associated bacterial infections. Anti-biofilm strategies targeting QS signalling, EPS matrix degradation, c-di-GMP-mediated dispersal, and persister cell eradication represent the most promising therapeutic frontier for infections that resist conventional antibiotics.